Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 329-333 , June 2010

Iron and reactive oxygen species activity in parkinsonian substantia nigra

  • Anna Wypijewska

      Affiliations

    • Department of Biophysics, Institute of Experimental Physics, University of Warsaw, Poland
    • ,
  • Jolanta Galazka-Friedman

      Affiliations

    • Faculty of Physics, Warsaw University of Technology, Poland
    • ,
  • Erika R. Bauminger

      Affiliations

    • Racah Institute of Physics, Hebrew University in Jerusalem, Israel
    • ,
  • Zbigniew K. Wszolek

      Affiliations

    • Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
    • ,
  • Katherine J. Schweitzer

      Affiliations

    • Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
    • ,
  • Dennis W. Dickson

      Affiliations

    • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA
    • ,
  • Andrzej Jaklewicz

      Affiliations

    • Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Poland
    • ,
  • Danek Elbaum

      Affiliations

    • Institute of Physics, Polish Academy of Sciences, Warsaw, Poland
    • ,
  • Andrzej Friedman

      Affiliations

    • Department of Neurology, Medical University of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland
    • Corresponding Author InformationCorresponding author. Tel./fax: +48 223265815.

Received 5 October 2009 ,Revised 11 February 2010 ,Accepted 12 February 2010.

References 

  1. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction?. Ann Neurol. 1992;32(Suppl):S10–S15
  2. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neurol Transm. 1988;74:199–205
  3. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia. 1993;4:61–65
  4. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol. 1994;36:876–881
  5. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114:1953–1975
  6. Youdim MB, Ben-Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand Suppl. 1989;126:47–54
  7. Uitti RJ, Rajput AH, Rozdilsky B, Bickis M, Wollin T, Yuen WK. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci. 1989;16:310–314
  8. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 1995;65:710–724
  9. Galazka-Friedman J, Bauminger ER, Friedman A, Barcikowska M, Hechel D, Nowik I. Iron in parkinsonian and control substantia nigra: a Mossbauer spectroscopy study. Mov Disord. 1996;11:8–16
  10. Friedman A, Galazka-Friedman J, Bauminger ER. Iron as a trigger of neurodegeneration in Parkinson's disease. Handb Clin Neurol. 2007;83:493–505
  11. Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P. Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem. 1995;65:923–926
  12. Dubiel SM, Zablotna-Rypien B, Mackey JB. Magnetic properties of human liver and brain ferritin. Eur Biophys J. 1999;28:263–267
  13. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161–203
  14. Koziorowski D, Friedman A, Arosio P, Dziewulska D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Parkinsonism Relat Disord. 2007;13:214–218
  15. Gerlach M, Riederer P, Double KL. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:S185–S188
  16. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem. 2001;76:1766–1773
  17. Galazka-Friedman J, Bauminger ER, Friedman A, Koziorowski D. Szlachta K- Human nigral and liver iron – comparison by Mössbauer spectroscopy, electron microscopy and ELISA. Hyperfine Interact. 2005;165:285–288
  18. Fasano M, Bergamasco B, Lopiano L. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem. 2006;96:909–916
  19. Bolzoni F, Giraudo S, Lopiano L, Bergamasco B, Fasano M, Crippa PR. Magnetic investigations of human mesencephalic neuromelanin. Biochim Biophys Acta. 2002;1586:210–218
  20. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A. 2004;101:9843–9848
  21. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement disorders society scientific issues committee movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467–486
  22. Bauminger ER, Harrison PM, Nowik I, Treffry A. Mossbauer spectroscopic study of the initial stages of iron-core formation in horse spleen apoferritin: evidence for both isolated Fe(III) atoms and oxo-bridged Fe(III) dimers as early intermediates. Biochemistry. 1989;28:5486–5493
  23. Ma Y, de Groot H, Liu Z, Hider RC, Petrat F. Chelation and determination of labile iron in primary hepatocytes by pyridinone fluorescent probes. Biochem J. 2006;395:49–55
  24. Brzyska M, Bacia A, Elbaum D. Oxidative and hydrolytic properties of beta-amyloid. Eur J Biochem. 2001;268:3443–3454
  25. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta. 2009;1790:606–614
  26. Tapiero H, Townsend DM, Tew KD. Trace elements in human physiology and pathology: copper. Biomed Pharmacother. 2003;57:386–398
  27. Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci. 2005;233:145–162
  28. Barnham KJ, Bush AI. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol. 2008;12:222–228
  29. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology. 2006;67(7 Suppl. 2):S8–S11
  30. Gassen M, Youdim MBH. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol. 1997;80:159–166

☆ The review of this paper was entirely handled by an Associate Editor, Vincenzo Bonifati.

PII: S1353-8020(10)00045-3

doi: 10.1016/j.parkreldis.2010.02.007

Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 329-333 , June 2010

Article Tools

* Image Usage & Resolution